Award
National Cancer Institute 5R21CA291788-02
Preclinical efficacy of GPR56 antibody-drug conjugates and combination therapies for triple-negative breast cancer
Recipient
Not specified
Award Amount
$178,846.00
Ceiling
$178,846.00
Awarded
March 09, 2026
Identifier
5R21CA291788-02
NIH grant awarded for research on GPR56 antibody-drug conjugates and combination therapies for triple-negative breast cancer, focusing on preclinical efficacy and minimal toxicity.
Description
This is a NIH grant opportunity for research on GPR56 antibody-drug conjugates targeting triple-negative breast cancer, with a focus on preclinical efficacy and combination therapies involving PARP inhibitors. The project aims to generate and evaluate targeted therapies with minimal toxicity, using mouse models and patient-derived tumors.